Outcome of female and male patients in the RICOVER-60 study. Elderly female patients (upper graphs) benefited more from the addition of rituximab than elderly males (lower graphs). Upper row: female patients without rituximab (n = 287; gray curves) and female patients with rituximab (n = 285; black curves). Lower row: males without rituximab (n = 325; gray curves) and males with rituximab (n = 325; black curves).